.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
US Army
Farmers Insurance
Novartis
Julphar
Healthtrust
Fish and Richardson
Citi
UBS
Chubb

Generated: November 24, 2017

DrugPatentWatch Database Preview

MACUGEN Drug Profile

« Back to Dashboard

What is the patent landscape for Macugen, and when can generic versions of Macugen launch?

Macugen is a drug marketed by Valeant Pharms Llc and is included in one NDA. There are two patents protecting this drug.

This drug has three hundred and eighty-two patent family members in thirty-six countries and nine supplementary protection certificates in eight countries.

The generic ingredient in MACUGEN is pegaptanib sodium. One supplier is listed for this compound. Additional details are available on the pegaptanib sodium profile page.

Summary for MACUGEN

US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 44
Drug Prices:see details
DailyMed Link:MACUGEN at DailyMed

Pharmacology for MACUGEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: MACUGEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: MACUGEN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,610,841 Nucleotide-based prodrugs► Subscribe
5,763,566 Systematic evolution of ligands by exponential enrichment: tissue SELEX► Subscribe
5,707,796 Method for selecting nucleic acids on the basis of structure► Subscribe
6,048,698 Parallel SELEX.TM.► Subscribe
6,682,886 Bivalent binding molecules of 7 transmembrane G protein-coupled receptors► Subscribe
5,763,173 Nucleic acid ligand inhibitors to DNA polymerases► Subscribe
6,713,616 High affinity TGF.beta. nucleic acid ligands and inhibitors► Subscribe
6,030,776 Parallel SELEX► Subscribe
5,587,468 High affinity nucleic acid ligands to HIV integrase► Subscribe
5,869,641 High affinity nucleic acid ligands of CD4► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: MACUGEN

Country Document Number Estimated Expiration
Germany69333961► Subscribe
Australia8666998► Subscribe
Japan2010265300► Subscribe
Canada2630098► Subscribe
Australia5301996► Subscribe
Portugal1042348► Subscribe
Australia1825701► Subscribe
Australia732961► Subscribe
Australia726844► Subscribe
European Patent Office1203007► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: MACUGEN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0021France► SubscribePRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
2006004Lithuania► SubscribePRODUCT NAME: PEGAPTANIBUM; REG. NO/DATE: EU/1/05/325/001 20060131
C024/2006Ireland► SubscribeSPC024/2006:, EXPIRES: 20210130
20/2006Austria► SubscribePRODUCT NAME: PEGAPTANIB UND SALZE DAVON
2006004,C0957929Lithuania► SubscribePRODUCT NAME: PEGAPTANIBUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
0234Netherlands► Subscribe300234, 20171017, EXPIRES: 20210130
0957929/01Switzerland► SubscribePRODUCT NAME: PEGAPTANIB; REGISTRATION NUMBER/DATE: SWISSMEDIC 57459 15.02.2006
2006 00021Denmark► Subscribe
252Luxembourg► Subscribe91252, EXPIRES: 20210131
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Cipla
Harvard Business School
Cantor Fitzgerald
Farmers Insurance
Novartis
Citi
Boehringer Ingelheim
Federal Trade Commission
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot